Combination Chemotherapy in Treating Children With Progressive Brain Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: This randomized phase III trial is studying two different combination chemotherapy regimens and comparing how well they work in treating children with low-grade astrocytomas or other residual tumors of the brain.
Gender:
ALL
Ages:
9 years and below
Trial Updated:
09/06/2013
Locations: Geisinger Cancer Institute at Geisinger Health, Danville, Pennsylvania +4 locations
Conditions: Brain Tumors, Central Nervous System Tumors
Carboplatin and Vincristine Plus Radiation Therapy Followed By Adjuvant Chemotherapy in Treating Young Patients With Newly Diagnosed CNS Embryonal Tumors
Completed
RATIONALE: Drugs used in chemotherapy, such as carboplatin and vincristine, work in different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells. Combining carboplatin and vincristine with radiation therapy followed by adjuvant chemotherapy may kill more tumor cells. PURPOSE: Randomized phase II trial to study the effectiveness of combination chemotherapy plus radiation therapy followed adjuvant chemotherapy in tre... Read More
Gender:
ALL
Ages:
Between 3 years and 21 years
Trial Updated:
08/22/2013
Locations: Children's Hospital of Philadelphia, Philadelphia, Pennsylvania +2 locations
Conditions: Brain Tumors, Central Nervous System Tumors, Neuroblastoma
Lobradimil and Carboplatin in Treating Children With Brain Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Lobradimil may increase the effectiveness of a chemotherapy drug by making tumor cells more sensitive to the drug. PURPOSE: Phase II trial to study the effectiveness of carboplatin and lobradimil in treating children with brain tumors that have not responded to previous treatment.
Gender:
ALL
Ages:
21 years and below
Trial Updated:
08/14/2013
Locations: Geisinger Medical Center, Danville, Pennsylvania +4 locations
Conditions: Brain and Central Nervous System Tumors
Combination Chemotherapy in Treating Patients With Stage IIIB, Stage IV, or Recurrent Non-Small Cell Lung Cancer
Withdrawn
RATIONALE: Drugs used in chemotherapy such as gemcitabine, carboplatin, and paclitaxel use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known which chemotherapy regimen is more effective in treating non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of different combination chemotherapy regimens in treating patients who have stage IIIB, stage IV, or re... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
07/10/2013
Locations: Rosenfeld Cancer Center at Abington Memorial Hospital, Abington, Pennsylvania +17 locations
Conditions: Lung Cancer
Combination Chemotherapy With or Without Bone Marrow or Stem Cell Transplantation in Treating Men With Untreated Germ Cell Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. It is not known whether combining chemotherapy with bone marrow or peripheral stem cell transplantation is more effective than combination chemotherapy alone in treating men with germ cell tumors. PURPOSE: Randomized phase III trial to compare the effectiveness of combination chemotherapy with or without bone marrow or peripheral stem cell transplantation in treating men with... Read More
Gender:
MALE
Ages:
12 years and above
Trial Updated:
06/25/2013
Locations: CCOP - Geisinger Clinic and Medical Center, Danville, Pennsylvania +3 locations
Conditions: Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Testicular Germ Cell Tumor
Trastuzumab Plus Chemotherapy in Treating Patients With Advanced Non-small Cell Lung Cancer
Completed
RATIONALE: Monoclonal antibodies can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining monoclonal antibody therapy with chemotherapy may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of the monoclonal antibody trastuzumab plus carboplatin and paclitaxel in treating patients who have adva... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
06/20/2013
Locations: CCOP - Geisinger Clinical and Medical Center, Danville, Pennsylvania +7 locations
Conditions: Lung Cancer
Combination Chemotherapy and Peripheral Stem Cell Transplantation in Treating Patients With Neuroblastoma
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining chemotherapy with peripheral stem cell transplantation may allow the doctor to give higher doses of chemotherapy drugs and kill more tumor cells. PURPOSE: This randomized phase III trial is studying peripheral stem cell transplantation with treated peripheral stem cells following combination chemotherapy to see how well it works compared to peripheral stem cell trans... Read More
Gender:
ALL
Ages:
30 years and below
Trial Updated:
05/16/2013
Locations: Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Neuroblastoma
Carboplatin and Irinotecan in Treating Children With Refractory Solid Tumors
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of combining carboplatin and irinotecan in treating children who have refractory solid tumors.
Gender:
ALL
Ages:
Between 1 year and 21 years
Trial Updated:
04/03/2013
Locations: Children's Hospital of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Unspecified Childhood Solid Tumor, Protocol Specific
Vorinostat, Paclitaxel, and Carboplatin in Treating Patients With Advanced or Refractory Solid Tumors
Completed
This phase I trial is studying the side effects and best dose of vorinostat when given together with paclitaxel and carboplatin in treating patients with advanced or refractory solid tumors. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as paclitaxel and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving vorinostat toge... Read More
Gender:
ALL
Ages:
18 years and above
Trial Updated:
02/06/2013
Locations: University of Pittsburgh, Pittsburgh, Pennsylvania
Conditions: Unspecified Adult Solid Tumor, Protocol Specific
S9900: Surgery With or Without Combination Chemotherapy in Treating Patients With Non-small Cell Lung Cancer
Completed
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. It is not yet known if surgery plus combination chemotherapy is more effective than surgery alone for non-small cell lung cancer. PURPOSE: Randomized phase III trial to compare the effectiveness of surgery with or without combination chemotherapy in treating patients who have non-small cell lung cancer.
Gender:
ALL
Ages:
18 years and above
Trial Updated:
01/30/2013
Locations: Abington Memorial Hospital, Abington, Pennsylvania +22 locations
Conditions: Lung Cancer
Evaluation of Paclitaxel (Taxol, NSC #673089), Carboplatin (Paraplatin, NSC #241240), and BSI-201 (NSC #746045, IND #71,677) in the Treatment of Advanced, Persistent, or Recurrent Uterine Carcinosarcoma
Completed
To estimate the antitumor activity of paclitaxel, carboplatin, plus BSI-201 in patients with recurrent or advanced uterine carcinosarcomas. Based on data generated by BiPar/Sanofi, it is concluded that iniparib does not possess characteristics typical of the PARP inhibitor class. The exact mechanism has not yet been fully elucidated, however based on experiments on tumor cells performed in the laboratory, iniparib is a novel investigational anti-cancer agent that induces gamma-H2AX (a marker of... Read More
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
08/01/2012
Locations: Research Site, Abington, Pennsylvania +3 locations
Conditions: Uterine Carcinosarcoma
TLK286 (Telcyta) in Combination With Carboplatin (Paraplatin) Versus Doxil in Platinum Refractory or Resistant Ovarian Cancer
Completed
The purpose of this research study is to determine if TLK286 given in combination with carboplatin is more effective than liposomal doxorubicin in treating women who have recurrent ovarian epithelial cancer, fallopian tube cancer, or primary peritoneal cancer, that is refractory or resistant to platinum chemotherapy.
Gender:
FEMALE
Ages:
18 years and above
Trial Updated:
05/30/2012
Locations: Abington Memorial Hospital, Abington, Pennsylvania +9 locations
Conditions: Ovarian Neoplasms